A strategy of eight weeks of bedaquiline-linezolid is noninferior to a standard regimen for tuberculosis, according to a study published online Feb. 20 in the New England Journal of Medicine to coincide with the annual Conference ...
Feb 28, 2023
0
5
Chronic low back pain and other chronic back problems are the most common health problems in Austria: it is estimated that almost half of all Austrians suffer from chronic neck, low back or back pain, which is extremely burdensome ...
Feb 22, 2023
0
2
Most health and nutrition claims on infant formula products seem to be backed by little or no high quality scientific evidence, finds an international survey published by The BMJ today.
Feb 15, 2023
0
72
Radiotherapy does not improve survival rates in older patients with early breast cancer, new research suggests.
Feb 15, 2023
0
22
The neuroprotectant ApTOLL, a medication that may shield the brain from tissue damage, was linked to reduced death and disability among people being treated for stroke when used with standard treatments to restore blood flow, ...
Feb 13, 2023
0
21
Viral suppression of HIV by antiretroviral medications helps slow transmission of the disease and keep individuals living with it healthy, at times making viral loads so low they are undetectable even on blood tests. Sixty-five ...
Feb 9, 2023
0
3
A new paper in the British Journal of Surgery finds that patients undergoing liver surgery fare better in higher-volume hospitals; their mortality rates are lower.
Feb 7, 2023
0
2
In a new research paper published in Oncotarget, researchers report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib. They present data for ...
Feb 1, 2023
0
2
More women, even those at low risk for ovarian cancer, who have finished having children should have their fallopian tubes removed as a precaution to prevent the deadly disease, a leading research group has advised.
Feb 1, 2023
0
13
Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit ...
Jan 20, 2023
0
4
